<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473379</url>
  </required_header>
  <id_info>
    <org_study_id>PROFTC-I</org_study_id>
    <nct_id>NCT03473379</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy</brief_title>
  <acronym>PROFTC-I</acronym>
  <official_title>Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity - Italy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop and validate a patient-reported-outcome instrument
      (PROFTC-I: Patient Reported Outcome Financial Toxicity in Cancer - Italy) able to describe
      and measure financial problems of Italian patients receiving cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project will be conducted according to the methodology delineated by the International
      Society for Pharmacoeconomics and Outcome Research (ISPOR) Patient Reported Outcomes Content
      Validity Good Research Practices Task Force in the following phases: concept elicitation and
      coding, item generation and analysis, instrument refinement and internal validation, and
      external validation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of Patient reported outcome financial toxicity of cancer Italian(PROFTC-I) questionnaire</measure>
    <time_frame>48 months</time_frame>
    <description>During the development of the questionnaire, individual items (questions), response options, and type of scoring will be determined according to Phases 1-3. Subsequently a principal components analysis (explorative factor analysis) will be done with eigen value set at 1; internal reliability will be assessed by inter-item correlations and Cronbach's alpha ( minimum acceptable 0.70); intraclass correlation coefficient (minimum acceptable 0.80). Correlation of final instrument with the EORTC quality of life questionnaire (criterion validity) will be assessed with using Pearson correlation coefficient.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1: concept elicitation and coding</arm_group_label>
    <description>The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Item generation and analysis</arm_group_label>
    <description>The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3: Instrument refinement and internal validation</arm_group_label>
    <description>The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 4: External validation</arm_group_label>
    <description>In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with any type of solid cancer or haematological malignancy who has undergone
        medical treatment, including chemotherapy, target agents, immunotherapy, hormonal
        treatment, radiotherapy and combinations of such therapies, or their caregivers, will be
        recruited in northern, central and southern Italian hospitals..
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years)

          -  Histologically or cytologically confirmed diagnosis of any type of solid cancer or
             haematological malignancy

          -  Written Informed Consent provided

          -  Medical treatment (chemotherapy, target agents, immunotherapy, hormonal treatment,
             radiotherapy or combinations of such therapies) ongoing or terminated within the
             previous 3 months.

          -  Caregivers of patients who meet the above criteria

        Exclusion Criteria:

          -  Patients with major cognitive dysfunction or psychiatric disorders

          -  Patients who have never received anticancer medical or radiation treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Perrone</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Bryce</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi della Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Riva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università di Milano - University of Wolverhampton</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio Efficace</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University, Feinberg School of Medicine, GIMEMA,EORTC Quality of Life Group - Rappresentante GIMEMA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco De Lorenzo</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIMAC and European Cancer Patient Coalition</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabetta Iannelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Segretario Generale FAVO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Del Campo</last_name>
    <role>Principal Investigator</role>
    <affiliation>FAVO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Traclò</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIMAC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Di Maio</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO Ordine Mauriziano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano Frontini</last_name>
    <role>Principal Investigator</role>
    <affiliation>FICOG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Montesarchio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncologia, Azienda dei Colli, Napoli - CIPOMO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lara Gitto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro per gli Studi Economici e Internazionali - Economic Evaluation &amp; Health Technology Assessment (CEIS EEHTA), Università di Roma &quot;Tor Vergata&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Jommi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale; Osservatorio Farmaci, Cergas, SDA Bocconi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concetta Maria Vaccaro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Welfare e Salute CENSIS (Centro Studi Investimenti Sociali), Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone</last_name>
    <phone>0815903571</phone>
    <email>f.perrone@istitutotumori.na.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Bryce</last_name>
    <phone>0815903571</phone>
    <email>j.bryce@istitutotumori.na.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda dei Colli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori, IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena - IRCCS - IFO</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AO Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>economic difficulty, financial toxicity</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

